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ABSTRACT 
Some oncology outpatients experience a higher number of and more severe symptoms during 
chemotherapy (CTX). However, little is known about whether this high risk phenotype persists 
over time. Latent transition analysis (LTA) was used to examine the probability that patients 
remained in the same symptom class when assessed prior to the administration of and following 
their next dose of CTX. For the patients whose class membership remained consistent, 
differences in demographic and clinical characteristics, and quality of life (QOL) were evaluated. 
The Memorial Symptom Assessment Scale (MSAS) was used to evaluate symptom burden. 
LTA was used to identify subgroups of patients with distinct symptom experiences based on the 
occurrence of the MSAS symptoms. Of the 906 patients evaluated, 83.9% were classified in the 
same symptom occurrence class at both assessments. Of these 760 patients 25.0% were 
classified as Low-Low, 44.1% as Moderate-Moderate, and 30.9% as High-High. Compared to 
the Low-Low class, the other two classes were younger, more likely to be female and to report 
child care responsibilities, and had a lower functional status and a higher comorbidity scores. 
The two higher classes reported lower QOL scores. The use of LTA could assist clinicians to 
identify higher risk patients and initiate more aggressive interventions. 
 
Key words: cancer; chemotherapy; latent transition analysis; symptoms; predictive risk 
modeling; quality of life 
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INTRODUCTION 
 Patients receiving chemotherapy (CTX) report an average of ten co-occurring symptoms 
(Esther Kim et al., 2009). However, in several studies (Pud et al., 2008, Dodd et al., 2011, Dodd 
et al., 2010, Illi et al., 2012, Miaskowski et al., 2006), a significant amount of inter-individual 
variability was found in patients’ experiences with various multiple co-occurring symptoms. All 
five of these studies evaluated for subgroups of patients based on self-reports of the four most 
common symptoms associated with cancer and its treatment (i.e., pain, fatigue, sleep 
disturbance, depression). A consistent finding across all five studies was the identification of a 
subgroup of patients with low levels of all four symptoms and a subgroup of patients with high 
levels of all four symptoms. Equally important, patients in the “all high” subgroup reported worse 
functional status and poorer quality of life (QOL) outcomes. 
 While the aforementioned studies were limited to only four co-occurring symptoms, 
newer work has used the Memorial Symptom Assessment Scale (MSAS) (Portenoy et al., 1994) 
to identify high risk patients based on the occurrence of 32 symptoms (Ferreira et al., 2008, 
Gwede et al., 2008, Miaskowski et al., In press). In two of these studies (Ferreira et al., 2008, 
Gwede et al., 2008), two distinct symptom subgroups were identified. In the third study 
(Miaskowski et al., In press), four distinct symptom subgroups were found. Across these three 
studies, patients in the subgroup with the highest symptom occurrence rates reported 
decrements in functional status and QOL. Of note, across all eight studies cited above, clinical 
characteristics were not associated with subgroup membership. Variations in the total number of 
patient subgroups may be related to the heterogeneous nature of the samples in terms of 
cancer diagnoses and types of treatments, the number of symptoms evaluated, the dimension 
of the symptom experience (e.g., occurrence, severity) used to create the subgroups, and the 
statistical procedures used to identify the subgroups. 
 Recently, our research team reported on the use of latent class analysis (LCA) to identify 
three distinct groups of patients (i.e., latent classes) based on the relative occurrence rates for 
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25 symptoms on the MSAS prior to receiving their next cycle of CTX (Miaskowski et al., 2014a). 
Of the 582 patients evaluated, 36.1% were categorized in the low class (i.e., mean of 5.7 
symptoms); 50.0% were in the moderate class (i.e., mean of 12.9 symptoms); and 13.9% were 
in the all high class (i.e., mean of 20.3 symptoms). Of note, patients in the all high class were 
significantly younger and more likely to be female and nonwhite, and had lower levels of social 
support, lower socioeconomic status, poorer functional status, and a higher level of comorbidity. 
As noted previously, no other clinical characteristics were associated with latent class 
membership. At the conclusion of this paper, we suggested that the use of LCA may provide an 
effective way to identify patients with a higher symptom burden or a high risk symptom 
phenotype (Miaskowski et al., 2014a). 
 A question that remains unanswered is whether or not this high risk symptom phenotype 
persists following the administration of CTX. In other words, do patients who were classified, 
using LCA, into the low, moderate, and high classes remain in those symptom classes following 
the administration of their next dose of CTX? To answer this research question, we used latent 
transition analysis (LTA) (Collins and Lanza, 2010, Lanza et al., 2003), to examine the 
probability that patients remained in the same class at their initial (i.e., prior to the administration 
of CTX) and subsequent (i.e., following the administration of their next dose of CTX) 
assessment. For the patients whose class membership remained consistent over the two time 
points, differences in demographic and clinical characteristics, as well as QOL outcomes were 
evaluated. 
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PATIENTS AND METHODS 
Patients and Settings 
 This study is part of an ongoing, longitudinal study of the symptom experience of 
oncology outpatients receiving CTX (Miaskowski et al., 2014a). Eligible patients were ≥18 years 
of age; had a diagnosis of breast, gastrointestinal (GI), gynecological (GYN), or lung cancer; 
had received CTX within the preceding four weeks; were scheduled to receive at least two 
additional cycles of CTX; were able to read, write, and understand English; and gave written 
informed consent. Patients were recruited from two Comprehensive Cancer Centers, one 
Veteran’s Affairs hospital, and four community-based oncology programs. A total of 1505 
patients were approached and 906 consented to participate (60.2% response rate). The major 
reason for refusal was being overwhelmed with their cancer treatment. 
Instruments 
 A demographic questionnaire obtained information on age, gender, ethnicity, marital 
status, living arrangements, education, employment status, and income. The Karnofsky 
Performance Status (KPS) scale (Karnofsky, 1977) was used to evaluate patients’ functional 
status. The Self-administered Comorbidity Questionnaire (SCQ) (Sangha et al., 2003) evaluated 
the occurrence, treatment, and functional impact of common comorbid conditions (e.g., 
diabetes, arthritis). 
 The MSAS was used to evaluate the occurrence, severity, frequency, and distress of 32 
symptoms commonly associated with cancer and its treatment. The MSAS is a self-report 
questionnaire designed to measure the multidimensional experience of symptoms. Patients 
were asked to indicate whether or not they had experienced each symptom in the past week 
(i.e., symptom occurrence). If they had experienced the symptom, they were asked to rate its 
frequency of occurrence, severity, and distress. The reliability and validity of the MSAS is well 
established in studies of oncology inpatients and outpatients (Portenoy et al., 1994). 
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 Quality of life (QOL) was evaluated using generic (i.e., Medical Outcomes Study-Short 
Form-12 (SF-12)) (Ware et al., 1996) and disease-specific (i.e., Quality of Life Scale-Patient 
Version (QOL-PV)) measures (Dow et al., 1996, Ferrell et al., 1995). Both measures have well-
established validity and reliability. Higher scores on both measures indicate a better QOL. 
Study Procedures 
 The study was approved by the Committee on Human Research at the University of 
California, San Francisco and by the Institutional Review Board at each of the study sites. From 
February 2010 to December 2013, all eligible patients were approached by the research staff in 
the infusion unit to discuss participation in the study. Written informed consent was obtained 
from all patients. Depending on the length of their CTX cycles, patients completed 
questionnaires in their homes, a total of six times over two cycles of CTX (i.e., prior to CTX 
administration (Time 1 and 4), approximately 1 week after CTX administration (Time 2 and 5), 
approximately 2 weeks after CTX administration (Time 3 and 6)). For this analysis, symptom 
occurrence data from the Time 1 (i.e., recovery from previous cycle) and Time 2 (i.e., acute 
symptoms) assessments were analyzed. Patients were asked to report on their symptom 
experience for the previous week. Medical records were reviewed for disease and treatment 
information. 
Data Analysis 
 Latent class analysis - LCA identifies latent classes based on an observed response 
pattern using categorical variables (Collins and Lanza, 2010, Lanza et al., 2003, Nylund et al., 
2007a, Vermunt and Magdison, 2002). Prior to identifying the LTA model that described 
patients' transitions from classes at Time 1 to classes at Time 2, separate LCAs were done to 
identify subgroups of patients with similar symptom experiences at each of the two 
assessments. These analyses provided an estimate of the number of classes that might be 
expected at each assessment, so as to inform the LTA modeling of the class transitions. 
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 The LCAs and LTA were done using the symptom occurrence data from the MSAS. In 
order to have a sufficient number of patients with each symptom to perform the LCA and LTA, 
we identified the MSAS symptoms that occurred in at least 40% of the patients. This criterion 
was selected to provide assurance that sufficient information was available to identify classes 
that were not sample-specific, due to infrequent reports of symptoms. A total of 25 out of 32 
symptoms from the MSAS occurred in >40% of the patients. Following the identification of the 
number of latent classes at each assessment with LCA, the estimation of latent transition 
classes was performed.  
 The final number of latent classes for each LCA was selected based on the Bayesian 
Information Criterion (BIC), the Vuong, Lo, Mendel, and Rubin likelihood ratio test (VLMR), and 
entropy. Typically, the best fitting LCA model has the lowest BIC. This BIC criterion can be 
supplemented by an evaluation of the VLMR (Nylund et al., 2007b) which tests whether a model 
with K classes fits the data better than a model with one fewer class (the K-1 class model). If the 
VLMR is significant, it supports the K-class model as fitting the data better. If it is not significant, 
it indicates that too many classes were extracted and that the K-1 class model fits the data 
better than the K-class model. In addition, well-fitting models produce entropy values of >.80 
(Celeux and Soromenho, 1996). Finally, well-fitting models “make sense” conceptually and the 
estimated classes differ as might be expected on variables not used in the generation of the 
model. Because the VLMR is not available for LTA, the best fitting model was determined based 
on its BIC and entropy values. 
 Latent Transition Analysis – LTA allows for the identification of individuals who transition 
from latent classes at one point in time, to the same latent classes at a subsequent point in time, 
as well as individuals who move to different classes (Collins and Lanza, 2010, Lanza et al., 
2003, Nylund et al., 2007a). Symptom occurrence data from the MSAS was used to identify the 
latent classes of patients with similar symptom experiences at two time points during their CTX 
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cycle (i.e., Time 1 – week prior to CTX administration and Time 2 – week following CTX 
administration).  
 The LCA and LTA models were estimated using MplusTM Version 7 (Muthen and 
Muthen, 1998-2014). Estimation was carried out with robust Maximum-Likelihood (MLR) and the 
Expectation-Maximization (EM) algorithm (Muthen and Shedden, 1999). Given that the 
observed variables were dichotomies, estimation was carried out with a logit link. To protect 
against solutions that were identified based on a local maximum, from 800 to as many as 6,000 
random starts were used in the estimation of the model. This approach ensured that the best 
fitting log-likelihood was replicated with multiple models (Muthen and Muthen, 1998-2014). 
 Differences in demographic and clinical characteristics and QOL outcomes among the 
LTA classes, were evaluated using analyses of variance, Kruskal-Wallis, or Chi-Square tests 
with Bonferroni corrected post hoc contrasts, using SPSS version 22 (IBM, Armonk, NY). A p-
value of <.05 was considered statistically significant. All comparisons among the classes used 
actual values. Adjustments were not made for missing data. Therefore, the cohort for each of 
these analyses was dependent on the largest set of complete data among groups. 
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RESULTS 
Latent Class Analyses 
A total of 906 patients completed the MSAS at Time 1 and Time 2. A separate LCA was 
done for each time point. As shown in Supplementary Table 1, a three-class solution fit the data 
best at each time point. For both time points, the BIC was lower for the 3-class compared to the 
2-class solution and the VLMR was significant. While the BIC for the 4-class solution was 
smaller, the VLMR was not significant. These consistent results for the two time points 
suggested an upper limit to the number of classes that might be found over the two 
assessments with the LTA. The probability of occurrence of the 25 MSAS symptoms for the 
three class solutions for the Time 1 and Time 2 assessments are illustrated in Figures 1A and 
1B, respectively. 
Latent Transition Analysis 
First, the LTA models were fit with two classes at each of the two assessments. Then 
the models were fit with three classes at each of the two time points. To ensure that the LTA 
classes at the two times were comparable, the LTA models were fit assuming measurement 
invariance for latent class indicators at each time.  
As shown in Supplementary Table 2, the BIC was smaller for the 3-to-3-class LTA and 
entropy remained above .80. As shown in Table 1, an LTA solution with 3 classes at each 
assessment produces nine classes in the joint distribution. An inspection of Table 1 shows that 
the proportion of cases in the off-diagonal classes is much smaller than for the classes on the 
diagonal and that five of the off-diagonal classes consist of less than 3% of the sample. 
Therefore, we did not estimate models beyond three classes at each assessment. 
As shown in Table 1C, of the 906 patients who had evaluable data at Time 1 and Time 
2, 760 (83.9%) were classified in the same symptom occurrence classes at both assessments. 
Of these 760 patients, based on the relative occurrence rates for the 25 MSAS symptoms 
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across the latent classes, 25.0% were classified as Low-Low, 44.1% as Moderate-Moderate, 
and 30.9% as High-High (Figure 2). 
Differences in Patient Characteristics Among the Three Consistent LTA Classes 
 Table 2 summarizes the differences in demographic and clinical characteristics among 
the three consistent LTA classes. Compared to the Low-Low class, patients in the High-High 
and Moderate-Moderate classes were significantly younger, more likely to be female, more 
likely to report having child care responsibilities, and had a lower KPS score and a higher 
comorbidity score. In terms of specific comorbid conditions, compared to the Low-Low class, a 
higher percentage of patients in the High-High class reported the occurrence of anemia, 
depression, and back pain. With the exception of the KPS and comorbidity scores, as well as 
cancer diagnosis, none of the other clinical characteristics (i.e., time since diagnosis, types and 
number of prior treatments, presence or number of metastatic sites) differed among the LTA 
classes. For cancer diagnosis, pairwise contrasts found that compared to the High-High class, a 
higher percentage of patients in the Low-Low class had a GI cancer. Patients in the High-High 
class reported the occurrence of a significantly higher number of MSAS symptoms (19.3 + 4.2) 
than patients in the Moderate class (12.4 + 3.0). Patients in the Moderate-Moderate class 
reported a significantly higher number of symptoms than patients in the Low-Low class (5.5 + 
2.7). 
Differences in Quality of Life Scores Among the Latent Classes 
 As shown in Table 3, except for the spiritual well-being subscale, post hoc contrasts 
revealed that patients in the High-High class reported significantly lower scores on the QOL-PV 
subscale and total scores than patients in the Moderate-Moderate class. Patients in the 
Moderate-Moderate class reported significantly lower QOL-PV scores than patients in the Low-
Low class. 
 In terms of the SF-12 subscale and physical component summary (PCS) and mental 
component summary (MCS) scores, except for the physical functioning and PCS scores, post 
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hoc contrasts revealed the same pattern of between group differences in QOL scores (i.e., 
High-High < Moderate-Moderate < Low-Low). For the physical functioning and PCS scores, the 
pattern of between class differences was Moderate-Moderate class and High-High class < Low-
Low class. 
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DISCUSSION 
 To our knowledge, this study is the first to use LTA to evaluate for a stable symptom 
phenotype based on patients’ experiences with 25 common symptoms before and following a 
dose of CTX. Consistent with our previous report that used LCA to evaluate 582 patients in the 
current sample prior to their next dose of CTX (Miaskowski et al., 2014a), three distinct 
subgroups of patients with consistent symptom experiences were identified by LTA. In addition, 
the mean number of symptoms reported by each latent class is relatively consistent across both 
studies. While in the previous study, as well as in the Time 1 LCA done with this larger sample 
(Figure 1A), approximately 14% of the patients were categorized in the All High class, in the 
current LTA study, using both the pretreatment and post-treatment assessments, 30.9% of the 
patients were categorized in the High-High class (Figure 2). This finding suggests that two or 
more assessments may be warranted to categorize those patients who are in a “stable” lower or 
higher risk symptom phenotype. In addition, it should be noted that 75% of the patients in this 
study experienced moderate to high occurrence rates for 25 common symptoms from prior to 
through the first week following their dose of CTX. 
 As shown in Table 1, for 83.9% of the patients (n=760), their most likely latent class 
pattern remained the same from Time 1 to Time 2. In terms of patients who transitioned from a 
lower to a higher symptom class, 9.7% went up one class and 0.3% went up two classes. In 
terms of patients whose transition pattern was the opposite, 5.7% went down one class and 
0.3% went down two classes. Given the small sample sizes for each of these groups, one 
cannot readily evaluate the exact reasons for these different patterns of transition. 
 As shown in Table 4 and consistent with previous reports of multiple co-occurring 
symptoms in oncology outpatients (Oksholm et al., 2015, Trudel-Fitzgerald et al., 2012, Kirkova 
et al., 2012), the six symptoms that were among the top eleven in occurrence rates across the 
three LTA classes were lack of energy (0.512 to 0.976), difficulty sleeping (0.401 to 0.946), pain 
(0.341 to 0.855), hair loss (0.338 to 0.733), feeling drowsy (0.255 to 0.877), and nausea (0.184 
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to 0.727). Of note, lack of energy, difficulty sleeping, anxiety, and pain are symptoms commonly 
associated with cytokine-induced sickness behavior (Illi et al., 2012, Wang et al., 2010, Myers, 
2008, Dantzer et al., 2008). However, while depression is often reported to be a symptom 
associated with sickness behavior (Walker et al., 2014, Harrison et al., 2009, Dantzer, 2006), it 
(i.e., feeling sad on the MSAS) was only found in the top eleven occurring symptoms in patients 
in the High-High class. In fact, in the High-High class, worrying (0.946), feeling irritable (0.895), 
and feeling nervous (0.758) had very high occurrence rates. None of the four psychological 
symptoms were found in the top 11 occurring symptoms in the other two LTA classes. This 
finding suggests that in addition to interventions to treat physical symptoms, patients in the 
High-High class require more in depth mental health evaluation and more proactive and 
aggressive management of their psychological symptoms. This approach is warranted given the 
substantial body of evidence that has documented the negative long-term sequelae of ongoing 
and high levels of psychological distress in cancer patients (Stanton et al., 2015). 
 Consistent with our previous report in the same sample (Miaskowski et al., 2014a) as 
well as reports by others (Gwede et al., 2008, Ferreira et al., 2008), KPS and SCQ scores were 
associated with LTA class membership. While associations between a higher symptom burden 
and a higher level of comorbidity, as well as poorer functional status, are reported consistently 
in oncology patients (Pud et al., 2008, Dodd et al., 2011, Dodd et al., 2010, Miaskowski et al., 
2006, Ferreira et al., 2008, Gwede et al., 2008), additional research is warranted to further 
explicate these relationships. For example, the most common comorbid conditions in this 
sample were high blood pressure (31.2%), back pain (26.4%), and depression (20.1%). Many of 
the chronic conditions listed in Table 2 are associated with both acute and chronic symptoms. 
Therefore, future studies need to assess the impact of the symptoms associated with cancer 
and its treatment, as well as the symptoms associated with other chronic conditions, on latent 
class membership. In addition, future longitudinal studies need to evaluate, using statistical 
procedures like parallel process growth modeling (Cheong et al., 2003, Rose et al., 2009), 
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whether increases in symptom burden are associated with decreases in functional status or vice 
versa. Similar approaches could be used to evaluate for changes in patients’ symptom burden 
in relationship to changes in their comorbidity profiles. 
 While the majority of the characteristics associated with cancer and its treatment did not 
predict LTA class membership, compared to the High-High class, a relatively higher percentage 
of patients with GI cancer were in the Low-Low class. The exact reasons for this difference are 
not readily apparent and warrant investigation in future studies. 
 Compared to the Low-Low class, patients in the Moderate-Moderate and High-High 
classes were almost a half or a whole decade younger, respectively. While the association 
between younger age and higher symptom burden is reported in previous studies (Illi et al., 
2012, Miaskowski et al., 2014a, Cataldo et al., 2013, Ritchie et al., 2014), the underlying 
physiologic and psychological mechanisms for this association remain to be determined. 
However, because recent evidence suggests that an overlap exists between molecular 
mechanisms that govern both aging and cancer (Coppede, 2013, Kong et al., 2013, Menck and 
Munford, 2014, Teschendorff et al., 2013), patients with cancer may experience “premature 
biological aging” that is associated with a higher symptom burden. Alternatively, 
“chronologically” older patients may receive lower doses of CTX (Townsley et al., 2005, Kumar 
et al., 2007) or have a “response shift” in their perception of symptoms (Sprangers and 
Schwartz, 1999, Schwartz and Sprangers, 1999). 
 While female gender, years of education, and child care responsibilities were associated 
with a higher symptom burden in the current study, findings regarding these characteristics are 
inconsistent across studies (Dodd et al., 2011, Illi et al., 2012, Miaskowski et al., 2014b, Baldwin 
et al., 2010, Cheung et al., 2011, Miaskowski, 2004). In addition, while other studies found that 
being a member of an ethnic minority and reporting a lower socioeconomic status were 
associated with more severe symptoms (Miaskowski et al., 2014a), these associations were not 
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found in the current study. Additional research is warranted to confirm or refute these inconstant 
findings. 
 For both the generic (SF-12) and disease-specific (MQOLS-PV) measures of QOL, as 
symptom burden increased, QOL decreased. The decrements in QOL among the three latent 
classes represent not only statistically significant, but clinically meaningful decreases in QOL 
with effect sizes ranging from 0.44 to 1.54 (Sloan et al., 2003, Osoba, 1999). Taken together 
and consistent with previous reports (Illi et al., 2012, Miaskowski et al., 2014a, Ferreira et al., 
2008, Gwede et al., 2008), these findings provide evidence of the significant negative impact 
that multiple co-occurring symptoms have on patients’ ability to function and other QOL 
outcomes. 
 Several study limitations need to be acknowledged. Because patients were recruited at 
different points in their CTX treatment, symptom occurrence rates prior to the initiation of CTX 
are not available. In addition, the CTX drugs used varied based on the patients’ diagnoses and 
stages of disease. While we cannot rule out the potential contributions of these clinical 
characteristics to the patients’ symptom experiences, the relatively similar percentages of 
cancer diagnoses, evidence of metastatic disease, time since cancer diagnosis, and types of 
previous treatments suggest that the three LTA classes were relatively similar in terms of 
disease and treatment characteristics. While it is possible that patients in the Low-Low class 
were receiving more aggressive symptom management interventions, the occurrence rates for 
fatigue, sleep disturbance, and pain were high across the three LTA classes. Finally, it should 
be noted that given the fact that 40% of the patients who were approached declined to 
participate in this study because they were too overwhelmed with their treatment, this study may 
be underestimating the symptom burden of oncology patients undergoing CTX. Additional 
studies are needed to confirm our findings. 
 In the era of precision medicine (Collins and Varmus, 2015) and big data (Yoo et al., 
2014), coupled with the use of electronic medical records and smart phone technology (e.g. the 
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ASyMS/eSMART© system that is being evaluated as part of a grant from the European 
Commission (Kearney et al., 2009, Maguire et al., 2015)), it is conceivable that symptom data 
will be collected in “real time” from oncology patients receiving CTX. The use of analytic 
approaches like LTA, or the development of more sophisticated algorithms using techniques like 
machine learning (Bastanlar and Ozuysal, 2014, Yoo et al., 2014), will allow clinicians to 
analyze patients’ phenotypic and molecular data on an ongoing basis. The integration of these 
types of information across multiple patients will assist clinicians to identify patients at highest 
risk for the most severe symptom profiles and to pre-emptively or more aggressively treat their 
most common and severe symptoms. This type of risk profiling and aggressive symptom 
management should reduce oncology patients’ symptom burden and improve their QOL. 
  
20 
 
REFERENCES 
Baldwin C. M., Ervin A. M., Mays M. Z., Robbins J., Shafazand S., Walsleben J. & Weaver T. 
 (2010) Sleep disturbances, quality of life, and ethnicity: the sleep heart health study. 
 Journal of Clinical Sleep Medicine 6, 176-183. 
 
Bastanlar Y. & Ozuysal M. (2014) Introduction to machine learning. Methods in Molecular 
 Biology 1107, 105-128. 
 
Cataldo J. K., Paul S., Cooper B., Skerman H., Alexander K., Aouizerat B., Blackman V., 
 Merriman J., Dunn L., Ritchie C., Yates P. & Miaskowski C. (2013) Differences in the 
 symptom experience of older versus younger oncology outpatients: a cross-sectional 
 study. BMC Cancer 13, 6. 
 
Celeux G. & Soromenho G. (1996) An entropy criterion for assessing the number of clusters in a 
 mixture model. Journal of Classification 13, 195-212. 
 
Cheong J., Mackinnon D. P. & Khoo S. T. (2003) Investigation of mediational processes using 
 parallel process latent growth curve modeling. Structural Equation Modeling-a 
 Multidisciplinary Journal 10, 238-262. 
 
Cheung W. Y., Le L. W., Gagliese L. & Zimmermann C. (2011) Age and gender differences in 
 symptom intensity and symptom clusters among patients with metastatic cancer. 
 Supportive Care in Cancer 19, 417-423. 
 
Collins F. S. & Varmus H. (2015) A new initiative on precision medicine. New England Journal 
 of Medicine 372, 793-795. 
 
Collins L. M. & Lanza S. T. (2010) Latent class and latent transition analysis: with applications in 
 the Social, Behavioral, and Health Science, John Wiley & Sons, Hoboken, NJ. 
 
Coppede F. (2013) The epidemiology of premature aging and associated comorbidities. Clinical 
 Interventions in Aging 8, 1023-1032. 
 
Dantzer R. (2006) Cytokine, sickness behavior, and depression. Neurology Clinics 24, 441-460. 
 
Dantzer R., O'connor J. C., Freund G. G., Johnson R. W. & Kelley K. W. (2008) From 
 inflammation to sickness and depression: when the immune system subjugates the 
 brain. Nature Reviews Neuroscience 9, 46-56. 
 
Dodd M. J., Cho M. H., Cooper B. A. & Miaskowski C. (2010) The effect of symptom clusters on 
 functional status and quality of life in women with breast cancer. European Journal of 
 Oncology Nursing 14, 101-110. 
 
Dodd M. J., Cho M. H., Cooper B. A., Petersen J., Bank K. A., Lee K. A. & Miaskowski C. (2011) 
 Identification of latent classes in patients who are receiving biotherapy based on 
 symptom experience and its effect on functional status and quality of life. Oncology 
 Nursing Forum 38, 33-42. 
 
21 
 
Dow K. H., Ferrell B. R., Leigh S., Ly J. & Gulasekaram P. (1996) An evaluation of the quality of 
 life among long-term survivors of breast cancer. Breast Cancer Research and Treatment 
 39, 261-273. 
 
Esther Kim J. E., Dodd M. J., Aouizerat B. E., Jahan T. & Miaskowski C. (2009) A review of the 
 prevalence and impact of multiple symptoms in oncology patients. Journal of Pain and 
 Symptom Management 37, 715-736. 
 
Ferreira K. A., Kimura M., Teixeira M. J., Mendoza T. R., Da Nobrega J. C., Graziani S. R. & 
 Takagaki T. Y. (2008) Impact of cancer-related symptom synergisms on health-related 
 quality of life and performance status. Journal of Pain and Symptom Management 35, 
 604-616. 
 
Ferrell B. R., Dow K. H. & Grant M. (1995) Measurement of the quality of life in cancer 
 survivors. Quality of Life Research 4, 523-531. 
 
Gwede C. K., Small B. J., Munster P. N., Andrykowski M. A. & Jacobsen P. B. (2008) Exploring 
 the differential experience of breast cancer treatment-related symptoms: a cluster 
 analytic approach. Supportive Care in Cancer 16, 925-933. 
 
Harrison N. A., Brydon L., Walker C., Gray M. A., Steptoe A. & Critchley H. D. (2009) 
 Inflammation causes mood changes through alterations in subgenual cingulate activity 
 and mesolimbic connectivity. Biological Psychiatry 66, 407-414. 
 
Illi J., Miaskowski C., Cooper B., Levine J. D., Dunn L., West C., Dodd M., Dhruva A., Paul S. 
 M., Baggott C., Cataldo J., Langford D., Schmidt B. & Aouizerat B. E. (2012) Association 
 between pro- and anti-inflammatory cytokine genes and a symptom cluster of pain, 
 fatigue, sleep disturbance, and depression. Cytokine 58, 437-447. 
 
Karnofsky D. (1977) Performance scale, Plenum Press, New York. 
 
Kearney N., Mccann L., Norrie J., Taylor L., Gray P., Mcgee-Lennon M., Sage M., Miller M. & 
 Maguire R. (2009) Evaluation of a mobile phone-based, advanced symptom 
 management system (ASyMS) in the management of chemotherapy-related toxicity. 
 Supportive Care in Cancer 17, 437-444. 
 
Kirkova J., Rybicki L., Walsh D. & Aktas A. (2012) Symptom prevalence in advanced cancer: 
 age, gender, and performance status interactions. American Journal of Hospice and 
 Palliative Care 29, 139-145. 
 
Kong C. M., Lee X. W. & Wang X. (2013) Telomere shortening in human diseases. FEBS 
 Journal 280, 3180-3193. 
 
Kumar A., Soares H. P., Balducci L., Djulbegovic B. & National Cancer I. (2007) Treatment 
 tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized 
 trials conducted by five National Cancer Institute-sponsored cooperative groups. Journal 
 of Clinical Oncology 25, 1272-1276. 
 
Lanza S. T., Flaherty B. P. & Collins L. M. (2003) Latent class and latent transition analysis. In: 
 Handbook of Psychology: Research Methods in Psychology, (eds Schinka, J. A. & 
 Velicer, W. F.), pp. 663-685. John Wiley & Sons, Inc., Hoboken, NJ. 
22 
 
Maguire R., Ream E., Richardson A., Connaghan J., Johnston B., Kotronoulas G., Pedersen V., 
 Mcphelim J., Pattison N., Smith A., Webster L., Taylor A. & Kearney N. (2015) 
 Development of a novel remote patient monitoring system: the advanced symptom 
 management system for radiotherapy to improve the symptom experience of patients 
 with lung cancer receiving radiotherapy. Cancer Nursing 38, E37-47. 
 
Menck C. F. & Munford V. (2014) DNA repair diseases: What do they tell us about cancer and 
 aging? Genetic and Molecular Biology 37, 220-233. 
 
Miaskowski C. (2004) Gender differences in pain, fatigue, and depression in patients with 
 cancer. Journal of the National Cancer Institute 32, 139-143. 
 
Miaskowski C., Cooper B. A., Melisko M., Chen L. M., Mastick J., West C., Paul S. M., Dunn L. 
 B., Schmidt B. L., Hammer M., Cartwright F., Wright F., Langford D. J., Lee K. & 
 Aouizerat B. E. (2014a) Disease and treatment characteristics do not predict symptom 
 occurrence profiles in oncology outpatients receiving chemotherapy. Cancer 120, 2371-
 2378. 
 
Miaskowski C., Cooper B. A., Paul S. M., Dodd M., Lee K., Aouizerat B. E., West C., Cho M. & 
 Bank A. (2006) Subgroups of patients with cancer with different symptom experiences 
 and quality-of-life outcomes: a cluster analysis. Oncology Nursing Forum 33, E79-89. 
 
Miaskowski C., Dunn L., Ritchie C., Paul S. M., Cooper B., Aouizerat B. E., Alexander K., 
 Skerman H. & Yates P. (In press) Latent class analysis reveals distinct subgroups of 
 patients based on symptom occurrence and demographic and clinical characteristics. 
 Journal of Pain and Symptom Management. 
 
Miaskowski C., Paul S. M., Cooper B., West C., Levine J. D., Elboim C., Hamolsky D., Abrams 
 G., Luce J., Dhruva A., Langford D. J., Merriman J. D., Kober K., Baggott C., Leutwyler 
 H. & Aouizerat B. E. (2014b) Identification of patient subgroups and risk factors for 
 persistent arm/shoulder pain following breast cancer surgery. European Journal of 
 Oncology Nursing 18, 242-253. 
 
Muthen B. & Shedden K. (1999) Finite mixture modeling with mixture outcomes using the EM 
 algorithm. Biometrics 55, 463-469. 
 
Muthen L. K. & Muthen B. O. (1998-2014) Mplus User's Guide (7th ed.), 7th edn, Muthen & 
 Muthen, Los Angeles, CA. 
 
Myers J. S. (2008) Proinflammatory cytokines and sickness behavior: implications for 
 depression and cancer-related symptoms. Oncology Nursing Forum 35, 802-807. 
 
Nylund K., Bellmore A., Nishina A. & Graham S. (2007a) Subtypes, severity, and structural 
 stability of peer victimization: what does latent class analysis say? Child Development 
 78, 1706-1722. 
 
Nylund K. L., Asparouhov T. & Muthen B. O. (2007b) Deciding on the number of classes in 
 latent class analysis and growth mixture modeling: A Monte Carlo simulation study. 
 Structural Equation Modeling 14, 535-569. 
  
23 
 
Oksholm T., Rustoen T., Cooper B., Paul S. M., Solberg S., Henriksen K., Kongerud J. S. & 
 Miaskowski C. (2015) Trajectories of symptom occurrence and severity from before 
 through five months after lung cancer surgery. J Pain Symptom Manage. 
 
Osoba D. (1999) Interpreting the meaningfulness of changes in health-related quality of life 
 scores: lessons from studies in adults. International Journal of Cancer 12, 132-137. 
 
Portenoy R. K., Thaler H. T., Kornblith A. B., Lepore J. M., Friedlander-Klar H., Kiyasu E., Sobel 
 K., Coyle N., Kemeny N., Norton L. & et al. (1994) The Memorial Symptom Assessment 
 Scale: an instrument for the evaluation of symptom prevalence, characteristics and 
 distress. European Journal of Cancer 30A, 1326-1336. 
 
Pud D., Ben Ami S., Cooper B. A., Aouizerat B. E., Cohen D., Radiano R., Naveh P., Nikkhou-
 Abeles R., Hagbi V., Kachta O., Yaffe A. & Miaskowski C. (2008) The symptom 
 experience of oncology outpatients has a different impact on quality-of-life outcomes. 
 Journal of Pain and Symptom Management 35, 162-170. 
 
Ritchie C., Dunn L. B., Paul S. M., Cooper B. A., Skerman H., Merriman J. D., Aouizerat B., 
 Alexander K., Yates P., Cataldo J. & Miaskowski C. (2014) Differences in the symptom 
 experience of older oncology outpatients. Journal of Pain and Symptom Management 
 47, 697-709. 
 
Rose J. H., Kypriotakis G., Bowman K. F., Einstadter D., O'toole E. E., Mechekano R. & 
 Dawson N. V. (2009) Patterns of adaptation in patients living long term with advanced 
 cancer. Cancer 115, 4298-4310. 
 
Sangha O., Stucki G., Liang M. H., Fossel A. H. & Katz J. N. (2003) The Self-Administered 
 Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health 
 services research. Arthritis and Rheumatism 49, 156-163. 
 
Schwartz C. E. & Sprangers M. A. (1999) Methodological approaches for assessing response 
 shift in longitudinal health-related quality-of-life research. Social Science and Medicine 
 48, 1531-1548. 
 
Sloan J. A., Cella D., Frost M. H., Guyatt G. & Osoba D. (2003) Quality of life III: translating the 
 science of quality-of-life assessment into clinical practice-an example-driven approach 
 for practicing clinicians and clinical researchers. Clinical Therapeutics 25 Suppl D, D1-5. 
 
Sprangers M. A. & Schwartz C. E. (1999) The challenge of response shift for quality-of-life-
 based clinical oncology research. Annals of Oncology 10, 747-749. 
 
Stanton A. L., Rowland J. H. & Ganz P. A. (2015) Life after diagnosis and treatment of cancer in 
 adulthood: Contributions from psychosocial oncology research. American Psychologist 
 70, 159-174. 
 
Teschendorff A. E., West J. & Beck S. (2013) Age-associated epigenetic drift: implications, and 
 a case of epigenetic thrift? Human Molecular Genetics 22, R7-R15. 
 
Townsley C., Pond G. R., Peloza B., Kok J., Naidoo K., Dale D., Herbert C., Holowaty E., Straus 
 S. & Siu L. L. (2005) Analysis of treatment practices for elderly cancer patients in 
 Ontario, Canada. Journal of Clinical Oncology 23, 3802-3810. 
24 
 
Trudel-Fitzgerald C., Savard J. & Ivers H. (2012) Evolution of cancer-related symptoms over an 
 18-month period. Journal of Pain and Symptom Management 45, 1007-1018. 
 
Vermunt J. K. & Magdison J. (2002) Latent class cluster analyses, Cambridge University Press, 
 New York. 
 
Walker A. K., Kavelaars A., Heijnen C. J. & Dantzer R. (2014) Neuroinflammation and 
 comorbidity of pain and depression. Pharmacology Reviews 66, 80-101. 
 
Wang X. S., Shi Q., Williams L. A., Mao L., Cleeland C. S., Komaki R. R., Mobley G. M. & Liao 
 Z. (2010) Inflammatory cytokines are associated with the development of symptom 
 burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain 
 Behavior and Immunity 24, 968-974. 
 
Ware J., Jr., Kosinski M. & Keller S. D. (1996) A 12-Item Short-Form Health Survey: 
 construction of scales and preliminary tests of reliability and validity. Medical Care 34, 
 220-233. 
 
Yoo C., Ramirez L. & Liuzzi J. (2014) Big data analysis using modern statistical and machine 
 learning methods in medicine. International Neurourology Journal 18, 50-57. 
 
  
25 
 
Figure legends 
Figure 1A – Probability of symptom occurrence for each of the latent classes for the 25 
symptoms on the Memorial Symptom Assessment Scale that occurred in >40% of the total 
sample (n=906) at Time 1 (i.e., Prior to next dose of chemotherapy). 
Figure 1B - Probability of symptom occurrence for each of the latent classes for the 25 
symptoms on the Memorial Symptom Assessment Scale that occurred in >40% of the total 
sample (n=906) at Time 2 (i.e., Following next dose of chemotherapy). The percentages on 
each figure indicate the percentage of patients in each of the latent classes. 
 
Figure 2 - Probability of symptom occurrence for each of the latent transition classes for the 25 
symptoms on the Memorial Symptom Assessment Scale that occurred in >40% of the total 
sample (n=760). The percentages on each figure indicate the percentage of patients in each of 
the latent classes. 
 


Table 1 - Latent Transition Class Counts and Proportions for Three-to-Three Classes Using 
Symptom Occurrence Ratings for Time 1 to Time 2 
 
A.  Three-Class to Three-Class Solution 
 
Time Class Count Proportion 
1 1 264.73 0.292 
 2 374.81 0.414 
 3 266.45 0.294 
2 1 251.18 0.277 
 2 434.76 0.480 
 3 220.06 0.243 
 
 
B.  Three-Class to Three-Class Pattern 
 
T1 Class T2 Class Count Proportion 
1 1 224.39 0.248 
1 2 35.33 0.039 
1 3 5.01 0.006 
2 1 22.77 0.025 
2 2 318.08 0.351 
2 3 33.97 0.037 
3 1 4.02 0.004 
3 2 81.34 0.090 
3 3 181.08 0.200 
 
C.  Actual Classification of Patients Based on Their Most Likely Latent Class Pattern from Time 
1 to Time 2 
 
Class 
Latent 
Class 
Pattern 
Number of 
Patients 
Percentage of 
Patients 
Class Names 
1 1 - 1 235 25.94 High-High 
2 1 – 2 25 2.76 High-Moderate 
3 1 - 3 3 0.33 High-Low 
4 2 – 1 13 1.43 Moderate-High 
5 2 – 2 335 36.98 Moderate-Moderate 
6 2 – 3 27 2.98 Moderate-Low 
7 3 – 1 3 0.33 Low-High 
8 3 – 2 75 8.28 Low-Moderate 
9 3 - 3 190 20.97 Low-Low 
 
Table 2 – Differences in Demographic and Clinical Characteristics Among the Three Latent Transition Analysis Classes (n=760) 
 
 
Characteristic Low-Low 
(1) 
n=190 
25.0% 
Moderate-
Moderate (2) 
n=335 
44.1% 
High-High 
(3) 
n=235 
30.9% 
Statistics 
Mean (SD) Mean (SD) Mean (SD) 
Age (years)  61.4 (10.6) 57.0 (11.9) 54.3 (12.1) F=19.9, p<.0001 
1 > 2 > 3 
Education (years) 15.7 (3.2) 16.5 (2.8) 16.1 (3.0) F=4.34, p=.013 
1 < 2 
Body mass index (kg/m2) 26.1 (5.6) 26.3 (5.8) 25.9 (5.6) F=0.30, p=.741 
Karnofsky Performance Status score 87.4 (9.7) 79.7 (11.8) 74.8 (12.0) F=58.25, p<.0001 
1 > 2 > 3  
Self-administered Comorbidity Questionnaire score 4.5 (2.5) 5.5 (3.1) 6.4 (3.3) F=19.85, p<.0001 
1 < 2 < 3 
Time since diagnosis (mean in years) 1.9 (3.2) 2.1 (3.7) 2.1 (4.1) KW, p=.871 
Time since diagnosis (median in years) 0.44 0.44 0.44 
Number of prior cancer treatments 1.6 (1.6) 1.7 (1.5) 1.8 (1.5) F=1.34, p=.263 
Number of metastatic sites including lymph node involvementa 1.3 (1.2) 1.2 (1.2) 1.2 (1.2) F=0.42, p=.656 
Number of metastatic sites excluding lymph node involvement 0.9 (1.1) 0.8 (1.1) 0.8 (1.0) F=0.74, p=.477 
Mean number of MSAS symptoms (out of 32) 5.5 (2.7) 12.4 (3.0) 19.3 (4.2) F=880.63, p<.0001 
1 < 2 < 3 
 
 % (n) % (n) % (n)  
Gender (% female) 68.9 (131) 78.2 (262) 89.8 (211) Χ2=31.96, p<.0001 
1 < 2 < 3 
Self-reported ethnicity 
 White 
 Non-white 
 
71.0 (130) 
29.0 (53) 
 
72.9 (240) 
27.1 (89) 
 
68.4 (158) 
31.6 (73) 
 
Χ2=1.37, p=.505 
Married or partnered (% yes) 70.1 (131) 67.1 (222) 62.7 (146) Χ2=2.64, p=.266 
Lives alone (% yes) 17.0 (32) 19.9 (66) 23.9 (56) Χ2=3.16, p=.206 
Currently employed (% yes) 37.2 (70) 37.4 (125) 28.6 (67) Χ2=5.43, p=.066 
Annual household income 
 Less than $30,000 
 $30,000 to $70,000 
 $70,000 to $100,000 
 Greater than $100,000 
 
16.7 (27) 
24.1 (39) 
17.9 (29) 
41.4 (67) 
 
15.9 (49) 
22.7 (70) 
13.6 (42) 
47.9 (148) 
 
22.0 (46) 
18.7 (39) 
19.6 (41) 
39.7 (83) 
 
 
KW=9.47, p=.230 
 
Child care responsibilities (% yes) 15.7 (29) 24.0 (79) 29.1 (67) Χ2=10.40, p=.006 
1 < 2 and 3 
Elder care responsibilities (% yes) 6.9 (12) 9.9 (30) 7.0 (15) Χ2=1.95, p=.378 
Common comorbidities (% yes) 
 Heart disease 
 High blood pressure 
 Lung disease 
 Diabetes 
 Ulcer or stomach disease 
 Kidney disease 
 Liver disease 
 
 Anemia 
 
 Depression 
 
 Osteoarthritis 
 
 Back pain 
 
 Rheumatoid arthritis 
 
4.7 (9) 
34.7 (66) 
12.6 (24) 
8.4 (16) 
2.6 (5) 
0.0 (0) 
7.4 (14) 
 
6.3 (12) 
 
5.8 (11) 
 
10.5 (20) 
 
15.8 (30) 
 
3.2 (6)  
 
5.7 (19) 
31.9 (107) 
11.0 (37) 
9.3 (31) 
4.2 (14) 
0.9 (3) 
3.3 (11) 
 
13.1 (44) 
 
14.9 (50) 
 
9.6 (32) 
 
24.8 (83) 
 
3.9 (13) 
 
4.3 (10) 
27.2 (64) 
11.9 (28) 
7.7 (18) 
6.4 (15) 
1.7 (4) 
7.7 (18) 
 
18.3 (43) 
 
39.1 (92) 
 
16.2 (38) 
 
37.4 (88) 
 
3.4 (8) 
 
Χ2=0.62, p=.733 
Χ2=2.92, p=.233 
Χ2=0.31, p=.857 
Χ2=0.45, p=.797 
Χ2=3.58, p=.167 
Χ2=3.34, p=.188 
Χ2=6.34, p=.042 
No significant pw contrasts 
Χ2=13.32, p=.001 
1<3 
Χ2=82.81, p<.0001 
1<2<3 
Χ2=6.214, p=.045 
No significant pw contrasts 
Χ2=26.19, p<.0001 
1 and 2 <3 
Χ2=0.21, p=.902 
Cancer diagnosis 
 Breast cancer 
 Gastrointestinal cancer 
 Gynecological cancer 
 Lung cancer 
 
34.7 (66) 
35.8 (68) 
14.7 (28) 
14.7 (28) 
 
41.5 (139) 
27.5 (92) 
16.7 (56) 
14.3 (48) 
 
46.0 (108) 
21.3 (50) 
24.7 (58) 
8.1 (19) 
Χ2=23.36, p=.001 
 
1>3 
Prior cancer treatment 
 No prior treatment 
 Only surgery, CTX, or RT 
 Surgery and CTX, or surgery and RT, or CTX and RT 
 Surgery and CTX and RT 
 
27.6 (51) 
35.1 (65) 
23.8 (44) 
13.5 (25) 
 
23.4 (77) 
41.6 (137) 
20.1 (66) 
14.9 (49) 
 
15.9 (37) 
45.9 (107) 
21.5 (50) 
26.7 (39) 
 
 
Χ2=11.25, p=.081 
 
Metastatic sites 
 No metastasis 
 Only lymph node metastasis 
 Only metastatic disease in other sites 
 Metastatic disease in lymph nodes and other sites 
 
29.1 (55) 
20.1 (38) 
28.6 (54) 
22.2 (42) 
 
33.3 (111) 
23.1 (77) 
23.7 (79) 
19.8 (66) 
 
36.1 (84) 
21.0 (49) 
19.7 (46) 
23.2 (54) 
 
 
Χ2=6.33, p=.387 
 
aTotal number of metastatic sites evaluated was 9. 
 
Abbreviations: CTX = chemotherapy, kg = kilograms, KW = Kruskal Wallis, m2 = meters squared, pw= pair-wise,  RT = radiation therapy, SD = 
standard deviation 
Table 3 – Differences in Disease Specific and Generic Quality of Life Scores Among the Three Latent Transition Analysis Classes (n=760) 
 
 
Characteristic Low-Low 
(1) 
n=190 
25.0% 
Moderate-
Moderate (2) 
n=335 
44.1% 
High-High 
(3) 
n=235 
30.9% 
Statistics 
Mean (SD) Mean (SD) Mean (SD) 
MULTIDIMENSIONAL QUALITY OF LIFE SCALE 
Physical well-being 8.1 (1.3) 6.6 (1.6) 5.5 (1.7) F=153.26, p < .001 
1 > 2 > 3 
Psychological well-being 6.9 (1.5) 5.7 (1.7) 4.1 (1.5) F=170.35 p < .001 
1 > 2 > 3 
Social well-being 7.1 (1.7) 5.8 (1.8) 4.4 (1.7) F=119.97, p<.0001 
1 > 2 > 3  
Spiritual well-being 5.4 (2.2) 5.3 (2.1) 5.2 (2.1) F=0.58, p = .562 
Total QOL score 6.9 (1.2) 5.8 (1.3) 4.6 (1.2) F=183.88 p < .001 
1 > 2 > 3 
SF12 SCORES 
Physical functioning 65.6 (34.0) 48.0 (32.8) 42.3 (32.5) F=25.89, p < .001 
1 > 2 and 3 
Role physical 70.6 (26.2) 51.1 (27.6) 40.5 (26.8) F=63.54, p < .001 
1 > 2 > 3 
Bodily pain 91.3 (17.9) 76.4 (25.9) 64.1 (29.2) F=58.64, p<.0001 
1 > 2 > 3 
General health 73.1 (22.6) 64.1 (27.3) 51.9 (28.8) F=32.58, p < .001 
1 > 2 > 3 
Vitality 62.9 (22.6) 42.0 (24.5) 35.0 (24.8) F=72.61, p < .001 
1 > 2 > 3 
Social functioning 85.9 (21.8) 67.1 (29.5) 52.1 (30.3) F=73.36, p<.0001 
1 > 2 > 3 
Role emotional 87.7 (22.0) 78.2 (25.5) 62.8 (27.8) F=50.89, p < .001 
1 > 2 > 3 
Mental health 83.9 (16.9) 74.6 (18.2) 57.7 (20.2) F=108.83, p < .001 
1 > 2 > 3 
Physical Component Summary score 46.2 (9.2) 40.0 (10.3) 38.3 (10.0) F=33.07, p<.0001 
1 > 2 and 3 
Mental Component Summary score 55.3 (8.6) 50.2 (9.4) 42.5 (9.8) F=92.45, p<.0001 
1 > 2 > 3 
 
Abbreviations: SD = standard deviation 
Table 4 – Probability of Occurrence for the 25 MSAS Symptoms For Each of the Three Latent Transition Class in 
Descending Order of Occurrence 
 
Rank 
Order 
High-High P Moderate-Moderate P Low-Low P 
1 Lack of energy .976 Lack of energy .966 Lack of energy .512 
2 Worrying .946 Difficulty sleeping .735 Difficulty sleeping .401 
3 Difficulty sleeping  .903 Feeling drowsy .690 Pain .341 
4 Feeling sad .895 Pain .676 Hair loss .338 
5 
Difficulty concentrating 
.892 
Nausea 
.575 
Numbness and tingling in 
hands/feet 
.331 
6 
Feeling drowsy 
.887 
Difficulty concentrating 
.563 
Changes in the way food 
tastes 
.284 
7 
Feeling irritable 
.859 
Numbness and tingling in 
hands/feet 
.556 
Feeling drowsy 
.255 
8 
Pain 
.855 
Changes in the way food 
tastes 
.535 
Constipation 
.186 
9 Feeling nervous .758 Lack of appetite .490 Cough .185 
10 Hair loss .733 Hair loss .487 Nausea .184 
11 Nausea .727 Dry mouth .482 Dry mouth .172 
12 I don’t look like myself .721 Constipation .454 Hot flashes .166 
13 
Numbness and tingling in 
hands/feet 
.712 
Worrying 
.391 
Difficulty concentrating 
.163 
14 
Changes in the way food 
tastes 
.695 
Feeling sad 
.376 
I don’t look like myself 
.162 
15 Lack of appetite .675 Dizziness .368 Worrying .159 
16 Constipation .642 Feeling irritable .350 Changes in skin .146 
17 Changes in skin .622 Changes in skin .339 Diarrhea .136 
18 Dry mouth .612 I don’t look like myself .324 Lack of appetite .124 
19 Feeling bloated .598 Diarrhea .315 Feeling irritable .113 
20 Sweats .552 Cough .304 Feeling sad .111 
21 Dizziness .529 Hot flashes .288 Sweats .110 
22 
Hot flashes 
.509 
Feeling bloated 
.270 
Problems with sexual 
interest 
.109 
23 
Problems with sexual 
interest 
.501 
Sweats 
.269 
Feeling bloated 
.099 
24 Cough .452 Problems with sexual interest .251 Dizziness .086 
25 Diarrhea .405 Feeling nervous .226 Feeling nervous .077 
 
Supplementary Table 1 – Latent Class Solutions and Fit Indices for the Time 1 and Time 2 
Assessments Using Symptom Occurrence Ratingsa 
 
Time 1 Assessment – Prior to Next Dose of Chemotherapy 
Model LL AIC BIC VLMR Entropy 
2 Class -13465.34 27032.68 27277.55 2375.10**** .84 
3 Classb -13217.76 26589.51 26959.21 495.17**** .83 
4 Class -13084.89 26375.78 26870.31 265.73ns .80 
Time 2 Assessment – Following the Next Dose of Chemotherapy 
2 Class -13286.83 26675.67 26920.53 2320.59**** .83 
3 Classb -13021.47 26196.94 26566.64 530.73**** .81 
4 Class -12892.35 25990.71 26485.24 258.23ns .79 
 
ns Not significant; * p < .05; ** p < .01; *** p < .001; **** p < .0001 
 
a In order to have a sufficient number of patients with each symptom to perform the latent class 
analyses, the MSAS symptoms that occurred in at least 40% of the patients were identified. This 
criterion was selected to provide assurance that sufficient information was available to identify 
classes that were not sample-specific, due to infrequent reports of symptoms. A total of 25 out 
of 32 symptoms from the MSAS occurred in >40% of the patients. 
 
bThe 3-class solution was selected because the VLMR was significant for the 3-class solution, 
indicating that three classes fit the data better than two classes, and the VLMR was not 
significant for the 4-class solution, indicating that too many classes had been extracted.  
 
Note. LL = log-likelihood; AIC = Akaike Information Criterion, BIC = Bayesian Information 
Criterion; VLMR = Vuong-Lo-Mendell-Rubin likelihood ratio test for the K vs. K-1 model. 
 
 
Supplementary Table 2 - Latent Transition Solutions and Fit Indices for Two-to-Two and Three-
to-Three Classes Using Symptom Occurrence Ratingsa for Time 1 to Time 2 
 
Model LL AIC BIC Entropy 
2 classes -26645.54 53397.07 53651.95 .86 
3 classesb -26073.41 52312.82 52711.97 .85 
 
aIn order to have a sufficient number of patients with each symptom to perform the latent class 
analyses, the MSAS symptoms that occurred in at least 40% of the patients were identified. This 
criterion was selected to provide assurance that sufficient information was available to identify 
classes that were not sample-specific, due to infrequent reports of symptoms. A total of 25 out 
of 32 symptoms from the MSAS occurred in >40% of the patients. 
 
bThe 3-to-3-class solution was selected because the BIC was smaller than the 2-to-2-class 
solution.  
 
Note. LL = log-likelihood; AIC = Akaike Information Criterion, BIC = Bayesian Information 
Criterion. 
 
